Dollar General Corp. (NYSE:DG), a rival chain, has said it’s not interested in a merger with Family Dollar. And Wal-Mart wouldn’t have much use for the company’s stores because they’re too small for its Express format, Montagna said. Dollar General Corp. (NYSE:DG) stock performance was 7.35% in last session and finished the day at $62.25. Traded volume was 25.42million shares in the last session and the average volume of the stock remained 4.58million shares. The beta of the stock remained 0.25. Dollar General Corp. (NYSE:DG) insider ownership is 0.10%.

Arcos Dorados Holding Inc (NYSE:ARCO) rose more than 6 percent in the current trading session after Bank of America Merrill Lynch upgraded the Argentina-based company from “Underperform” to “Buy” with a price target of $14.16 per share for the stock, in a research report published this morning. ARCO has a market capitalization of $2.14 billion. Arcos Dorados Holding Inc (NYSE:ARCO) rose 7.91 percent to $10.37 Monday on volume of 1.14million shares. The intra-day range of the stock was $9.92 to $10.50. Arcos Dorados Holding Inc (NYSE:ARCO) has a market capitalization of $2.18billion.

WisdomTree Investments Inc. (NASDAQ:WETF) was upgraded by analysts at Morgan Stanley from an equal weight rating to an overweight rating. WisdomTree Investments, Inc. (NASDAQ:WETF)’s stock on June 09, 2014 reported a decrease of -0.65% to the closing price of $12.25. Its fifty two weeks range is $9.11 -$18.50. The total market capitalization recorded $1.63billion. The overall volume in the last trading session was 4.62million shares. In its share capital, WETF has 133.27million outstanding shares.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) CEO Jean Jacques Bienaime unloaded 2,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $61.20, for a total transaction of $122,400.00. Following the transaction, the chief executive officer now directly owns 229,157 shares of the company’s stock, valued at approximately $14,024,408. On Monday, shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) dropped -0.37% to close the day at $61.51. Company return on investment (ROI) is -8.50% and its monthly performance is recorded as 8.33%. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) quarterly revenue growth is -20.32%.